Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$8.95
-2.0%
C$8.43
C$3.18
C$9.98
C$215.78M1.0437,895 shs15,836 shs
HEXO Corp. stock logo
HEXO
HEXO
$0.71
+2.5%
$0.87
$0.66
$3.84
$31.24M1.35880,508 shs305,500 shs
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
$1.95
-3.0%
$2.33
$1.78
$5.59
$68.88M3.42659,216 shs702,511 shs
BioSyent Inc. stock logo
RX
BioSyent
C$8.59
+0.9%
C$8.60
C$7.03
C$9.26
C$99.73M0.935,744 shs2,600 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
-1.97%+3.11%+6.29%+39.63%+174.54%
HEXO Corp. stock logo
HEXO
HEXO
0.00%0.00%0.00%0.00%-52.67%
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
-2.74%-8.02%-32.99%-12.16%-38.49%
BioSyent Inc. stock logo
RX
BioSyent
+0.94%-1.15%-0.12%-1.15%+12.14%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
0.6593 of 5 stars
1.50.00.00.02.91.71.3
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/AN/AN/AN/A
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
0.25 of 5 stars
0.01.00.00.03.21.70.6
BioSyent Inc. stock logo
RX
BioSyent
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
3.00
BuyC$8.00-10.61% Downside
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/A
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
1.00
SellN/AN/A
BioSyent Inc. stock logo
RX
BioSyent
N/AN/AN/AN/A

Current Analyst Ratings

Latest CPH, HEXO, NINE, and RX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/14/2024
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSpeculative Buy ➝ BuyC$4.75 ➝ C$8.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$21.16M10.20C$2.54 per share3.53C$3.36 per share2.66
HEXO Corp. stock logo
HEXO
HEXO
$146.20M0.21N/AN/A$2.44 per share0.29
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
$609.53M0.11$0.85 per share2.30($1.01) per share-1.93
BioSyent Inc. stock logo
RX
BioSyent
C$31.59M3.16C$2.79 per share3.07C$2.96 per share2.90

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$20.38MC$1.108.14N/A96.32%28.19%8.06%8/8/2024 (Estimated)
HEXO Corp. stock logo
HEXO
HEXO
-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/A
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
-$32.21M-$1.01N/AN/AN/A-5.28%N/A-6.48%8/1/2024 (Estimated)
BioSyent Inc. stock logo
RX
BioSyent
C$6.46MC$0.5316.21N/A20.45%18.97%11.39%5/16/2024 (Confirmed)

Latest CPH, HEXO, NINE, and RX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/16/2024N/A
BioSyent Inc. stock logo
RX
BioSyent
C$0.08N/A-C$0.08N/AN/AN/A
3/14/2024Q4 2023
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$0.15C$0.41+C$0.26C$0.41C$7.31 millionC$6.70 million
3/13/2024Q4 2023
BioSyent Inc. stock logo
RX
BioSyent
C$0.17C$0.12-C$0.05C$0.12C$8.80 millionC$8.27 million
3/7/2024Q4 2023
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
-$0.35-$0.30+$0.05-$0.30$142.00 million$144.07 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
N/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/A
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
N/AN/AN/AN/AN/A
BioSyent Inc. stock logo
RX
BioSyent
C$0.182.10%N/A33.96%N/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
0.44
9.19
2.67
HEXO Corp. stock logo
HEXO
HEXO
0.01
0.41
0.24
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
N/A
2.22
1.56
BioSyent Inc. stock logo
RX
BioSyent
3.51
6.48
6.91

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
1.12%
HEXO Corp. stock logo
HEXO
HEXO
7.78%
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
57.61%
BioSyent Inc. stock logo
RX
BioSyent
1.37%

Insider Ownership

CompanyInsider Ownership
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
44.51%
HEXO Corp. stock logo
HEXO
HEXO
4.69%
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
6.20%
BioSyent Inc. stock logo
RX
BioSyent
38.45%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
524.11 millionN/ANot Optionable
HEXO Corp. stock logo
HEXO
HEXO
1,27744.00 million41.93 millionOptionable
Nine Energy Service, Inc. stock logo
NINE
Nine Energy Service
1,15735.33 million33.38 millionOptionable
BioSyent Inc. stock logo
RX
BioSyent
N/A11.61 millionN/ANot Optionable

CPH, HEXO, NINE, and RX Headlines

SourceHeadline
BioSyent (RX) Scheduled to Post Quarterly Earnings on ThursdayBioSyent (RX) Scheduled to Post Quarterly Earnings on Thursday
marketbeat.com - May 10 at 8:30 AM
Increases to CEO Compensation Might Be Put On Hold For Now at BioSyent Inc. (CVE:RX)Increases to CEO Compensation Might Be Put On Hold For Now at BioSyent Inc. (CVE:RX)
finance.yahoo.com - May 10 at 7:04 AM
AMD RDNA 4: Everything we know about the RX 8000 seriesAMD RDNA 4: Everything we know about the RX 8000 series
msn.com - May 9 at 11:02 AM
Insider Buying: BioSyent Inc. (CVE:RX) Insider Purchases 5,100 Shares of StockInsider Buying: BioSyent Inc. (CVE:RX) Insider Purchases 5,100 Shares of Stock
insidertrades.com - May 9 at 9:41 AM
Used Lexus RX 350 for sale near meUsed Lexus RX 350 for sale near me
cars.com - May 4 at 8:00 AM
BioSyent (CVE:RX) Stock Passes Below Fifty Day Moving Average of $8.60BioSyent (CVE:RX) Stock Passes Below Fifty Day Moving Average of $8.60
americanbankingnews.com - April 30 at 4:36 AM
BioSyent Inc.: BioSyent Announces Extension of RepaGyn and Proktis-M AgreementBioSyent Inc.: BioSyent Announces Extension of RepaGyn and Proktis-M Agreement
finanznachrichten.de - April 16 at 10:57 AM
Used Lexus RX 350 for sale under $12,000 near meUsed Lexus RX 350 for sale under $12,000 near me
cars.com - April 6 at 5:32 PM
BioSyent Inc.s (CVE:RX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?BioSyent Inc.'s (CVE:RX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
finance.yahoo.com - April 4 at 10:20 AM
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive YearFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year
markets.businessinsider.com - April 3 at 2:49 PM
Used 2016 Lexus RX 350 for sale near meUsed 2016 Lexus RX 350 for sale near me
cars.com - March 27 at 7:20 PM
2022 Lexus RX2022 Lexus RX
jdpower.com - March 23 at 2:42 PM
BioSyent Inc.: BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023BioSyent Inc.: BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
finanznachrichten.de - March 21 at 5:39 AM
Earnings call: BioSyent Inc. reports robust growth in Q4 and FY 2023Earnings call: BioSyent Inc. reports robust growth in Q4 and FY 2023
uk.investing.com - March 16 at 7:33 PM
BioSyent Named to 2024 TSX Venture 50BioSyent Named to 2024 TSX Venture 50
markets.businessinsider.com - February 21 at 10:25 AM
RX:CA BioSyent Inc.RX:CA BioSyent Inc.
seekingalpha.com - February 17 at 10:24 AM
Lexus RX 500hLexus RX 500h
cars.com - February 16 at 11:35 PM
BioSyent Declares First Quarter 2024 DividendBioSyent Declares First Quarter 2024 Dividend
markets.businessinsider.com - February 6 at 11:12 PM
2003 Lexus RX 300 Review2003 Lexus RX 300 Review
autoblog.com - December 21 at 12:43 PM
2021 Lexus RX2021 Lexus RX
motortrend.com - December 17 at 6:54 PM
2017 Lexus RX2017 Lexus RX
motortrend.com - December 17 at 1:53 PM
2018 Lexus RX2018 Lexus RX
motortrend.com - December 17 at 1:53 PM
Lexus RXLexus RX
consumerreports.org - December 4 at 12:26 PM
Is It Smart To Buy BioSyent Inc. (CVE:RX) Before It Goes Ex-Dividend?Is It Smart To Buy BioSyent Inc. (CVE:RX) Before It Goes Ex-Dividend?
finance.yahoo.com - November 24 at 8:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cipher Pharmaceuticals logo

Cipher Pharmaceuticals

TSE:CPH
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
HEXO logo

HEXO

NYSE:HEXO
HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.
Nine Energy Service logo

Nine Energy Service

NYSE:NINE
Nine Energy Service, Inc. operates as an onshore completion services provider that targets unconventional oil and gas resource development in North American basins and internationally. It offers cementing services, including blending high-grade cement and water with various solid and liquid additives to create a cement slurry that is pumped between the casing and the wellbore of the well. The company also provides open hole and cemented completion tool products, such as liner hangers and accessories, fracture isolation packers, frac sleeves, stage one prep tools, casing flotation tools, specialty open hole float equipment, disk subs, composite cement retainers, and centralizers that provide pinpoint frac sleeve system technologies. In addition, it offers wireline services consisting of plug-and-perf completions, which is a multistage well completion technique for cased-hole wells that consists of deploying perforating guns and isolation tools to a specified depth; and coiled tubing services, which perform wellbore intervention operations utilizing a continuous steel pipe that is transported to the wellsite wound on a large spool. The company was formerly known as NSC-Tripoint, Inc. and changed its name to Nine Energy Service, Inc. in October 2011. Nine Energy Service, Inc. was incorporated in 2011 and is headquartered in Houston, Texas.
BioSyent logo

BioSyent

CVE:RX
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.